Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates
Follow the latest updates of the outbreak聽on our聽timeline.
Sanofi vaccines division Sanofi Pasteur has partnered with Translate Bio for the development of a messenger RNA (mRNA) vaccine against Covid-19.
Translate Bio has already started the production of several mRNA constructs. The company will leverage its mRNA platform for the discovery, design and manufacture of SARS-CoV-2 vaccine candidates.
Sanofi will contribute via its vaccine expertise and external research networks support. The aim is to progress vaccine candidates for further development.
Translate Bio has created 100g single-batch production using its mRNA therapeutics platform, while a separate manufacturing space is being built by a contract manufacturing partner to facilitate at least two 250g batches each month.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTranslate Bio CEO Ronald Renaud said: 鈥淥ur collaborative efforts to combat Covid-19 will leverage Translate Bio鈥檚 innovative mRNA platform as well as Sanofi鈥檚 vaccine expertise and ongoing Covid-19 research with the goal of advancing a novel mRNA vaccine rapidly to the clinic.鈥�
The alliance builds on an ongoing agreement signed by the companies in 2018 to develop mRNA vaccines for infectious diseases.
Sanofi Vaccines global head David Loew said: 鈥淲e are committed to leveraging different ways to address the Covid-19 public health crisis by testing treatments, as well as two vaccines using different platforms. We believe the more approaches we explore, the better our likelihood of success in achieving this goal.
鈥淗aving sufficient installed capacity will be key to satisfy the strong demand for vaccines we will probably see and based on the experience we鈥檝e had under the collaboration to date, we believe the Translate Bio mRNA platform could help us meet that need.鈥�
Last month, Sanofi Pasteur partnered with the US Department of Health and Human Services (HHS)鈥檚 Biomedical Advanced Research and Development Authority (BARDA) to develop a recombinant, protein-based vaccine candidate for Covid-19.
Furthermore, Sanofi and Regeneron 色界吧s launched a clinical programme of rheumatoid arthritis drug Kevzara to treat hospitalised patients with severe Covid-19.
